Cardiff Oncology, Inc.
CRDF- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001213037
In the last 90 days, Cardiff Oncology, Inc. insiders filed 2 open-market purchases and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $24.2M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Cardiff Oncology, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 55 | 53 | −2 |
| Shares | 7.05M | 5.99M | −1.06M (−15.0%) |
| Value | $11.6M | $8.81M | −$2.83M (−24.3%) |
New holders (3)
Institutions that held Cardiff Oncology, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Fifth Third Bancorp | 200 | $294 | 0.00% |
| BerganKDV Wealth Management, LLC | 1 | $2 | 0.00% |
| Sofos Investments, Inc. | 1 | $2 | 0.00% |
Sold out (5)
Institutions that held Cardiff Oncology, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Citigroup Inc | 651,161 | $1.07M |
| Belpointe Asset Management LLC | 11,454 | $18.9K |
| Tower Research Capital LLC (TRC) | 392 | $1.00K |
| CWM, LLC | 850 | $1.00K |
| Larson Financial Group LLC | 150 | $248 |